ALEXANDRIA, Va., July 3 -- United States Patent no. 12,343,383, issued on July 1, was assigned to Novo Nordisk A/S (Bagsvaerd, Denmark).
"High concentration insulin formulation" was invented by Jeppe Sturis (Vaerloese, Denmark), Svend Havelund (Bagsvaerd, Denmark) and Karen-Margrethe Pedersen (Copenhagen V, Denmark).
According to the abstract* released by the U.S. Patent & Trademark Office: "The invention concerns a soluble insulin preparation comprising NepsilonB29-hexadecandioyl-Gamma-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 Mug/ml to 1 Mug...